The International Center for Health Outcomes and Innovation Research at the Icahn School of Medicine at Mount Sinai and Mesoblast Ltd (MSB) have entered into a Memorandum of Understanding to conduct a confirmatory clinical trial using Mesoblast’s product candidate Revascor (MPC-150-IM) for reduction of gastrointestinal bleeding in end-stage heart failure patients implanted with a left ventricular assist device
http://crweworld.com/article/news-provided-by-globenewswire/1030122/memorandum-of-understanding-for-confirmatory-trial-to-support-marketing-approval-of-revascor-for-reduction-of-gastrointestinal-bleeding-in-lvad-patients
Ann: MoU for Confirmatory Trial for GI Bleeding in LVAD Patients, page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.35%) |
Mkt cap ! $1.113B | |||
| Open | High | Low | Value | Volume |
| $1.51 | $1.52 | $1.43 | $6.602M | 4.467M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14383 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 42900 | 4 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
